Risedronate Reduces Osteoclast Precursors and Cytokine Production in Postmenopausal Osteoporotic Women

Abstract

Our data show that risedronate is effective in lowering the number of circulating osteoclast precursors, their formation, vitality, and activity in cultures, and in reducing the level of pro-osteoclastogenic cytokines in culture supernatants and in serum.